EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting noncoding RNAs to treat atherosclerosis

Miron Sopić iD, Sandra Vladimirov, Jelena Munjas, Tijana Mitić, Ignacio Fernando Hall iD, Amela Jusic, Dusan Ruzic, Yvan Devaux iD, AtheroNET COST Action CA21153 (https://atheronet.eu/)

British Journal of Pharmacology · 2025-01 · 182 (2) · 220-245

DOI: 10.1111/bph.16412 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Pharmacology, online erschienen am 08.05.2024. Verfasst von Miron Sopić und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Research Unit, Department of Precision Health, Luxembourg Institute of Health, Luxembourg, Luxembourg. Hauptthemen laut MEDLINE: Atherosclerosis, RNA, Untranslated. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 169 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020 Framework Programme, H2020 Marie Skłodowska-Curie Actions, Fonds National de la Recherche Luxembourg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Noncoding RNAs (ncRNAs) are pivotal for various pathological processes, impacting disease progression. The potential for leveraging ncRNAs to prevent or treat atherosclerosis and associated cardiovascular diseases is of great significance, especially given the increasing prevalence of atherosclerosis in an ageing and sedentary population. Together, these diseases impose a substantial socio‐economic burden, demanding innovative therapeutic solutions. This review explores the potential of ncRNAs in atherosclerosis treatment. We commence by examining approaches for identifying and characterizing atherosclerosis‐associated ncRNAs. We then delve into the functional aspects of ncRNAs in atherosclerosis development and progression. Additionally, we review current RNA and RNA‐targeting molecules in development or under approval for clinical use, offering insights into their pharmacological potential. The importance of improved ncRNA delivery strategies is highlighted. Finally, we suggest avenues for advanced research to accelerate the use of ncRNAs in treating atherosclerosis and mitigating its societal impact. LINKED ARTICLES This article is part of a themed issue Non‐coding RNA Therapeutics. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.2/issuetoc

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisRNA, UntranslatedHumansAnimals

Stichwörter der Autor:innen

RNAatherosclerosiscardiovascular diseasenoncoding RNAtherapeutics

Substanzen

RNA, Untranslated

Autor:innen und Institutionen

  • Cardiovascular Research Unit, Department of Precision Health, Luxembourg Institute of Health, Luxembourg, Luxembourg.
  • Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
  • BHF/University Centre for Cardiovascular Science, Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK.
  • HAYA Therapeutics SA, SuperLab Suisse - Bâtiment Serine, Lausanne, Vaud, Switzerland.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.

ORCID-Profile: Miron Sopić, Ignacio Fernando Hall, Yvan Devaux

Förderung

  • Horizon 2020 Framework Programme
  • H2020 Marie Skłodowska-Curie Actions
  • Fonds National de la Recherche Luxembourg
  • European Cooperation in Science and Technology
  • British Heart Foundation
  • Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja
  • HORIZON EUROPE Marie Sklodowska-Curie Actions

Zitieren

APA

Sopić, M., Vladimirov, S., Munjas, J., Mitić, T., Hall, I. F., Jusic, A., Ruzic, D., Devaux, Y., & AtheroNET COST Action CA21153 (https://atheronet.eu/) (2025). Targeting noncoding RNAs to treat atherosclerosis. British Journal of Pharmacology, 182(2), 220-245. https://doi.org/10.1111/bph.16412

Vancouver

Sopić M, Vladimirov S, Munjas J, Mitić T, Hall IF, Jusic A, et al. Targeting noncoding RNAs to treat atherosclerosis. British Journal of Pharmacology. 2025;182(2):220-245. doi:10.1111/bph.16412

BibTeX
@article{Sopi2025,
  author = {Sopić, Miron and Vladimirov, Sandra and Munjas, Jelena and Mitić, Tijana and Hall, Ignacio Fernando and Jusic, Amela and Ruzic, Dusan and Devaux, Yvan and AtheroNET COST Action CA21153 (https://atheronet.eu/), AtheroNET COST Action CA21153 (https://atheronet.eu/)},
  title = {Targeting noncoding RNAs to treat atherosclerosis},
  journal = {British Journal of Pharmacology},
  year = {2025},
  volume = {182},
  number = {2},
  pages = {220--245},
  doi = {10.1111/bph.16412}
}
Kostenlos starten →